No abstract

The oncogene Golgi phosphoprotein 3 (GOLPH3) has been found in several solid cancers, but its expression in glioma tumor tissues is unknown. Reverse transcription polymerase chain reaction and Western blot was used to investigate expression of GOLPH3 mRNA and protein, respectively, in 76 patients with glioma. Non-cancerous brain issues and lung cancer cells were used as controls. There were 45 males and 31 females (mean age 50.7 ± 12.8 years). Astrocytoma was found in 65 patients and glioblastoma in 11. No GOLPH3 expression was found in the non-cancerous brain tissues, but positive GOLPH3 protein was found in lung cancer cells. GOLPH3 mRNA and protein expression were identified in 40 patients with glioma (52.6%). Positive expression of GOLPH3 mRNA or protein was similar in patients with astrocytoma grades I-III and glioblastoma (P > 0.05). The highest mean value of GOLPH3 mRNA and protein was found in patients with glioblastoma (P < 0.01) whereas the lowest mean values were found in those with grade I astrocytoma (P < 0.01). We concluded that, in this pilot study, GOLPH3 expression was present in more than half of the patients with glioma. The amount of GOLPH3 expression in the glioma was associated with the severity of the tumor. Whether positive GOLPH3 gene expression can be used as a predictor for prognosis of the patients or as a therapeutic target for glioma requires further investigation.

While genetic alterations in several regulators of the cell cycle have a significant impact on the gastric carcinogenesis process, the prognostic role of them remains to be further elucidated. The TCGA-STAD training set were downloaded and the mRNA expression matrix of cell cycle genes was extracted and corrected for further analysis after taking the intersection with GSE84437 dataset. Differentially expressed mRNAs were identified between tumor and normal tissue samples in TCGA-STAD. Univariate Cox regression analysis and lasso Cox regression model established a novel seven-gene cell cycle signature (including GADD45B, TFDP1, CDC6, CDC25A, CDC7, SMC1A and MCM3) for GC prognosis prediction. Patients in the high-risk group shown significantly poorer survival than patients in the low-risk group. The signature was found to be an independent prognostic factor for GC survival. Nomogram including the signature shown some clinical net benefit for overall survival prediction. The signature was further validated in the GSE84437 dataset. In tissue microarray, CDC6 and MCM3 protein expression were significant differences by the immunohistochemistry-based H-score between tumor tissues and adjacent tissues, and CDC6 is an independent prognostic factor for GC. Interestingly, our GSEA revealed that low-risk patients were more related to cell cycle pathways and might benefit more from therapies targeting cell cycle. Our study identified a novel robust seven-gene cell cycle signature for GC prognosis prediction that may serve as a beneficial complement to clinicopathological staging. The signature might provide potential biomarkers for the application of cell cycle regulators to therapies and treatment response prediction.